Cara Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Cara Therapeutics Stock Forecast and Price Target
Cara Therapeutics's most recent price target of $5.00 for 2024 was provided by renowned analysts over the past few months, with an average prediction of $5.00. If this prediction is correct, Cara Therapeutics's stock could rise by 557.89 percent from its current trading price. The potential increase for the stock is $5.00 per share, with a possible range of $1.00 to $10.00. If you want to buy CARA stock, it might be a good idea to look at its competitors too.
557.89% Upside
Cara Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Cara Therapeutics's Price has decreased from $2.70 to $0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach $0.82 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$161.72 | Buy/Sell | $178.42 | 15.01% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$277.37 | Buy/Sell | $303.65 | 15.19% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.51 | Buy/Sell | $87.82 | 22.12% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$216.13 | Buy/Sell | $299.62 | 33.48% |
Cara Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Cara Therapeutics's Revenue has decreased from $135.08M to $20.97M – a 84.48% drop. In the next year, analysts predict that Revenue will reach $75.23M – an increase of 258.75%. For the next seven years, the forecast is for Revenue to grow by 2520.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.33 | Buy/Sell | $111.56 | 32.01% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.94 | Buy/Sell | $77.05 | 45.83% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$76.43 | Buy/Sell | $34.00 | 50.46% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$94.86 | Buy/Sell | $85.71 | 5.42% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.50 | Buy/Sell | $20.42 | 104.00% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Cara Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Cara Therapeutics has seen a decline in its EBITDA, from $5.59M to $-121.26M – a 2269.23% decrease. According to the 2 analysts polled, in the next year, Cara Therapeutics's EBITDA will fall by 57.89%, reaching $-51.06M. By 2030, professionals believe that Cara Therapeutics's EBITDA will have decreased by 340.39%, falling to $291.50M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$23.17 | Buy/Sell | $52.00 | 128.74% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.05 | Buy/Sell | $33.78 | 75.07% |
Cara Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Cara Therapeutics's EBIT has decreased by 2354.17%, from $5.39M to $-121.50M. For the next year, 7 analysts project Cara Therapeutics's EBIT to drop by 25.79%, reaching $-90.16M. By 2030, professionals believe that Cara Therapeutics's EBIT will decrease by 362.58%, reaching $319.04M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$39.35 | Buy/Sell | $63.29 | 95.68% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.08 | Buy/Sell | $42.58 | 16.82% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$33.66 | Buy/Sell | $40.00 | 29.23% |
Cara Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Cara Therapeutics's EPS has decreased from $0.18 to $0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach $-1.18 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.67 | Buy/Sell | $6.00 | 19.94% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.61 | Buy/Sell | $9.94 | 104.24% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.68 | Buy/Sell | $25.00 | 109.76% |
.jpg)